Shobana Sampath | Drug Formulation | Editorial Board Member

Assist. Prof. Dr. Shobana Sampath | Drug Formulation | Editorial Board Member

Assistant Professor at Vel Tech Rangarajan Dr.Sagunthala R&D Institute of Science and Technology | India

Assist. Prof. Dr. Shobana Sampath is an accomplished biotechnology researcher specializing in nanobiotechnology, cancer biology, immunology, and therapeutic nanoformulation, focusing on the development of biocompatible nanoparticles through green synthesis for disease mitigation. She has applied her research across antibacterial, antioxidant, anticancer, and antidiabetic applications using both cellular and molecular level analyses. Her Ph.D. work demonstrated novel biological applications of silver and zinc oxide nanoparticles, including mechanisms of apoptosis, cell-cycle arrest, and reactive oxygen species regulation in cancer systems, supported by toxicity-free validation in animal models. With a strong record of scientific publishing, she has produced 40 Scopus-indexed documents, 354 citations, and holds a Scopus h-index of 11. Her publications include high-impact SCI journals, addressing nanoparticles for targeted therapy, nanocomposite-based antimicrobial applications, eco-nanotechnology for sustainable health, and advanced biomaterials for aquaculture and regenerative medicine. She also contributes significantly to scholarly discourse as a reviewer for multiple international journals and as a Special Issue Editor for MDPI Sustainability (Q2), strengthening the scientific quality control ecosystem. Her authored and ongoing book chapters with renowned publishers such as Wiley, Springer Nature, and Elsevier-aligned imprints explore nanotechnology innovations for health, agriculture, and environmental sustainability. Actively engaged in academic leadership and research supervision, she continues to support translational outcomes in biotechnology, positioning her as a valuable contributor to global biomedical research and well-qualified for Editorial Board leadership roles.

Profiles : Scopus | ORCID | Google Scholar

Featured Publications

Sampath, S., Madhavan, Y., Muralidharan, M., Sunderam, V., & Lawrance, A. V. (2022). A review on algal mediated synthesis of metal and metal oxide nanoparticles and their emerging biomedical potential. Journal of Biotechnology, 360, 92–109. Cited by: 55

Sampath, S., Sunderam, V., Manjusha, M., Dlamini, Z., & Lawrance, A. V. (2024). Selenium nanoparticles: A comprehensive examination of synthesis techniques and their diverse applications in medical research and toxicology studies. Molecules, 29(4), 801. Cited by: 54

Sampath, S., Bhushan, M., Saxena, V., Pandey, L. M., & Singh, L. R. (2022). Green synthesis of Ag doped ZnO nanoparticles: Study of their structural, optical, thermal and antibacterial properties. Materials Technology, 37(13), 2785–2794. Cited by: 38

Shobana, S., Veena, S., Sameer, S. S. M., Swarnalakshmi, K., & Lawrance, L. A. (2020). Green synthesis of silver nanoparticles using Artocarpus hirsutus seed extract and its antibacterial activity. Current Pharmaceutical Biotechnology, 21(10), 980–989. Cited by: 38

Mohammed, S. S. S., Lawrance, A. V., Sampath, S., Sunderam, V., & Madhavan, Y. (2022). Facile green synthesis of silver nanoparticles from sprouted Zingiberaceae species: Spectral characterisation and its potential biological applications. Materials Technology, 37(8), 533–546. Cited by: 34

Dr. Yihai Liu | Translational Medicine | Best Researcher Award

Dr. Yihai Liu | Translational Medicine | Best Researcher Award

Dr. Yihai Liu | Nanjing Drum Tower Hospital | China

Dr. Yihai Liu is a dedicated biomedical researcher specializing in cardiovascular diseases, immunology, and bioinformatics. Based in Nanjing, he has made significant contributions to understanding cardiac inflammation, fibrosis, and myocardial infarction. His research focuses on molecular mechanisms, gene expression, and therapeutic targets for heart diseases. With numerous publications in high-impact journals, Dr. Liu is also an editor and reviewer for esteemed scientific journals. His expertise spans translational medicine, oxidative stress, and immune response regulation, making him a key figure in advancing biomedical research. Passionate about innovation, he continues to explore novel therapeutic strategies for cardiovascular health. 🧬❤️

Professional Profile:

Google Scholar

Suitability for the Best Researcher Award

Dr. Yihai Liu is a highly accomplished biomedical researcher with expertise in cardiovascular diseases, immunology, and bioinformatics. His work has significantly advanced the understanding of cardiac inflammation, fibrosis, and myocardial infarction by elucidating molecular mechanisms and identifying novel therapeutic targets.

Education & Experience 🎓💼

  • 🎓 B.Sc. – [University not specified]
  • 🎓 Ph.D. – [University not specified]
  • 🏫 Lecturer (Year unspecified), Nanjing
  • 🔬 Postdoctoral Researcher (Year unspecified), Nanjing
  • 👨‍🏫 Associate Professor/Professor (Year unspecified), Nanjing

Professional Development 📚🔍

Dr. Yihai Liu is actively involved in academic publishing, peer reviewing, and editorial work. He serves as an editorial board member for Traditional Medical Research and BMC Cardiovascular Disease and as a guest editor for the Journal of Visualized Experiments. Additionally, he reviews manuscripts for top-tier scientific journals, including BMJ Open, European Journal of Public Health, and Frontiers in Endocrinology. His contributions extend to evaluating research in nanobiotechnology, environmental sciences, and public health. With a strong commitment to scientific integrity and innovation, Dr. Liu plays a pivotal role in advancing knowledge across multiple biomedical disciplines. 🏅📖

Research Focus🧪🧬

Dr. Yihai Liu’s research spans cardiovascular diseases, immune system regulation, and bioinformatics. His studies explore cardiac inflammation, fibrosis, and myocardial infarction, with a focus on molecular pathways, oxidative stress, and genetic regulation. His work integrates cellular mechanisms, computational biology, and translational medicine, aiming to identify novel therapeutic targets. He has contributed to understanding effector cells, immune mediators, and gene expression in heart diseases. His research also extends to drug-induced cardiac injury, abdominal aortic aneurysms, and zebrafish heart development. Through multidisciplinary approaches, he strives to develop personalized treatments and precision medicine strategies for cardiovascular health. ❤️🩺

Awards & Honors 🏆🎖️

Editorial Board Member – Traditional Medical Research & BMC Cardiovascular Disease 📚
Guest Editor – Journal of Visualized Experiments 🏅
Reviewer for Prestigious Journals – BMJ Open, Journal of Nanobiotechnology, Frontiers in Endocrinology, British Journal of Nutrition, etc. ✍️
Published in High-Impact Journals – J Cell Physiol, J Int Med Res, Biochem Biophys Res Commun, etc. 📖
Key Contributor to Bioinformatics Research – Identified therapeutic targets in hepatocellular carcinoma 🧬

Publication Top Notes:

📌 miRNA-181a over-expression in mesenchymal stem cell-derived exosomes influenced inflammatory response after myocardial ischemia-reperfusion injury – Z Wei, S Qiao, J Zhao, Y Liu, Q Li, Z Wei, Q Dai, L Kang, B Xu  🔗 Cited by: 194
🍎 Association between composite dietary antioxidant index and hypertension: insights from NHANES – M Wu, J Si, Y Liu, L Kang, B Xu  📈 Cited by: 89
🦠 Neutrophil to lymphocyte ratio (NLR) as a prognostic marker for in-hospital mortality of patients with sepsis: A secondary analysis based on a single-center, retrospective study – J Ni, H Wang, Y Li, Y Shu, Y Liu  ⚕️ Cited by: 80
💊 Hyaluronic acid-coated polymeric micelles with hydrogen peroxide scavenging to encapsulate statins for alleviating atherosclerosis – D Mu, J Li, Y Qi, X Sun, Y Liu, S Shen, Y Li, B Xu, B Zhang  🔬 Cited by: 46
❤️ Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity – Y Liu, J Xu, M Wu, B Xu, L Kang 💉 Cited by: 45